Table 4.
Multiple hypothesis testing of factors associated with survival
| Breast cancer subtypes | RFS | OS | DMFS | ||||||
|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | P-value | HR | 95% CI | P-value | HR | 95% CI | P-value | |
| ER status | |||||||||
| ER+ | 1.85 | 1.57–2.18 | < 0.001 | 2.61 | 1.86–3.68 | < 0.001 | 2.92 | 2.09–4.07 | < 0.001 |
| ER- | 1.18 | 0.9–1.18 | 0.23 | 1.24 | 0.8–1.92 | 0.34 | 1.4 | 0.9–2.17 | 0.13 |
| PR status | |||||||||
| PR+ | 3.4 | 2.09–5.55 | < 0.001 | 6.34 | 1.26–31.88 | ns, 0.011 | 3.92 | 1.15–13.32 | ns, 0.018 |
| PR- | 1.51 | 1.11–2.05 | ns, 0.0081 | 2.79 | 0.99–7.82 | ns, 0.042 | 3.39 | 1.88–6.11 | < 0.001 |
| HER2 status | |||||||||
| HER2+ | 1.73 | 1.17–2.56 | ns, 0.0053 | 3.42 | 1.52–7.72 | 0.0017 | 1.78 | 0.94–3.39 | ns, 0.073 |
| HER2- | 2.12 | 1.79–2.51 | < 0.001 | 1.7 | 1.37–2.12 | < 0.001 | 1.93 | 1.58–2.36 | < 0.001 |
| Lymph node status | |||||||||
| Lymph node+ | 2.19 | 1.67–2.88 | < 0.001 | 1.72 | 1.18–2.5 | ns, 0.0044 | 2.03 | 1.4–2.94 | < 0.001 |
| Lymph node- | 1.82 | 1.52–2.17 | < 0.001 | 3 | 1.88–4.78 | < 0.001 | 2.39 | 1.8–3.19 | < 0.001 |
| Grade | |||||||||
| 1 | 3.12 | 1.8–5.42 | < 0.001 | 3.19 | 1.28–7.96 | ns, 0.0087 | 2.79 | 1.23–6.33 | ns, 0.011 |
| 2 | 1.99 | 1.56–2.55 | < 0.001 | 2.55 | 1.67–3.89 | < 0.001 | 2.61 | 1.85–3.68 | < 0.001 |
| 3 | 1.35 | 1.07–1.7 | ns, 0.011 | 1.25 | 0.89–1.77 | 0.19 | 1.75 | 1.13–2.73 | ns, 0.012 |
| TP53 status | |||||||||
| Mutated | 0.77 | 0.48–1.26 | 0.3 | 0.69 | 0.34–1.42 | 0.32 | 0.56 | 0.26–1.22 | 0.14 |
| Wild type | 1.82 | 1.16–2.85 | ns, 0.0077 | 2.56 | 1.38–4.76 | 0.0021 | 3.67 | 1.76–7.63 | < 0.001 |
ns Not significant after correction for multiple hypothesis testing; bold faced: remained significant